Quick Answer
Annovis Bio, Inc. reported Diluted EPS of $1.40 per share (loss) for fiscal year 2025.
Annovis Bio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.40 | +39.4% |
| 2024 | -$2.31 | +62.9% |
| 2023 | -$6.23 | -101.0% |
| 2022 | -$3.10 | -63.2% |
| 2021 | -$1.90 | -118.4% |
| 2020 | -$0.87 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.37 | +61.9% | -15.6% |
| June 30, 2025 | -$0.32 | +27.3% | +0.0% |
| March 31, 2025 | -$0.32 | +55.6% | +67.0% |
| September 30, 2024 | -$0.97 | +40.5% | -120.5% |
| June 30, 2024 | -$0.44 | +58.9% | +38.9% |
| March 31, 2024 | -$0.72 | +32.7% | +55.8% |
| September 30, 2023 | -$1.63 | -106.3% | -52.3% |
| June 30, 2023 | -$1.07 | -46.6% | +0.0% |
- Annovis Bio, Inc. showed an increase of +39.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Annovis Bio, Inc.’s diluted eps has declined by 60.9% (from $0.87 per share (loss) to $1.40 per share (loss)).
- The most recent figure is from Annovis Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: